These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32926176)

  • 21. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
    Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
    J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up effect of omalizumab in chronic spontaneous urticaria and its association with serum C-reactive protein levels.
    Baysak S; Sevim Kecici A; Dogan B
    Dermatol Ther; 2020 Jul; 33(4):e13663. PubMed ID: 32447802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.
    Agache I; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong PY; O'Mahony L; Schwarze J; Warner A; Werfel T; Palomares O; Jutel M
    Allergy; 2022 Jan; 77(1):17-38. PubMed ID: 34324716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
    Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
    Maurer M; Zuberbier T; Metz M
    Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose omalizumab use in patients with chronic spontaneous urticaria.
    Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria.
    Su O; Bahali AG; Onsun N
    Dermatol Ther; 2020 Nov; 33(6):e14192. PubMed ID: 32790183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comment on ''how does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?'': reply from author.
    Önder S; Ozturk M
    Cutan Ocul Toxicol; 2020 Mar; 39(1):73. PubMed ID: 31899976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria.
    Castagna J; Bernard L; Hacard F; Delcroix F; Darrigade AS; Nicolas JF; Decullier E; Nosbaum A; Bérard F
    Br J Dermatol; 2020 Dec; 183(6):1124-1126. PubMed ID: 32531805
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevalence of chronic urticaria refractory to antihistamines in Andalucia, Spain.
    Pereyra-Rodriguez JJ; Galán Gutiérrez M; Armario-Hita JC; Ruiz-Villaverde R
    Dermatol Ther; 2020 Nov; 33(6):e13866. PubMed ID: 32558086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of treatment response in chronic spontaneous urticaria.
    Fok JS; Kolkhir P; Church MK; Maurer M
    Allergy; 2021 Oct; 76(10):2965-2981. PubMed ID: 33539587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review.
    Staubach P; Peveling-Oberhag A; Lang BM; Zimmer S; Sohn A; Mann C
    J Dermatolog Treat; 2022 Mar; 33(2):1119-1122. PubMed ID: 32588687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.
    Folci M; Ramponi G; Brunetta E
    Adv Exp Med Biol; 2021; 1326():111-137. PubMed ID: 33385176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab in chronic inducible urticaria: A retrospective, real-life study.
    Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D
    Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853
    [No Abstract]   [Full Text] [Related]  

  • 36. Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Allergy; 2021 Apr; 76(4):1274-1277. PubMed ID: 33314187
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary report.
    Sellitto A; De Fanis U; Balestrieri A; Savoia A; Astarita C; Romano C
    Eur Ann Allergy Clin Immunol; 2017 Jul; 49(4):171-175. PubMed ID: 28752720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study.
    Di Bona D; Nettis E; Bilancia M; Ridolo E; Minenna E; Nizi MC; Albanesi M; Caiaffa MF; Macchia L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2482-2485.e2. PubMed ID: 33677081
    [No Abstract]   [Full Text] [Related]  

  • 39. Omalizumab improves perceived stress, anxiety, and depression in chronic spontaneous urticaria.
    Patella V; Zunno R; Florio G; Palmieri M; Palmieri S; Brancaccio R
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1402-1404. PubMed ID: 33248284
    [No Abstract]   [Full Text] [Related]  

  • 40. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
    Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.